You searched for Antibody candidate - Page 9 of 67

News and Trends 29 Aug 2019

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

…also fuel the expansion of HiFiBiO’s antibody production technology, which is based on screening hundreds of single immune cells at a time for the most effective antibody drug candidate. HiFiBiO…

August 29, 2019 - 2 minutesmins - By Jonathan Smith

In Depth 30 Apr 2025

The future of NSCLC treatment: what’s in store for the therapeutic space?

…candidates in the clinic trying to combat this inadequacy. And some of the candidates could be on their way beyond the clinic, as they are being evaluated in late-stage trials….

April 30, 2025 - 12 minutesmins - By Roohi Mariam Peter

Best in Biotech 30 Jan 2017

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

…shown significant advantages over antibody-drug conjugates in preclinical models. Clinical trials for the first candidate are due to start in 2017. Acacia Pharma focuses on conditions caused by aggressive therapies,…

January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro

Weekly Roundup 24 Nov 2023

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

…an antibody that was discovered based on WuXi Bio’s integrated technology platforms, so that Myricx can develop an ADC using the antibody, to target solid tumors, through its NMT-1 platform….

November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter

Best in Biotech 24 Oct 2024

Six biotech companies advancing multiple sclerosis therapies

…debilitating disease. Table of contents Biogen Leading multiple sclerosis drug candidate of Biogen: BIIB091 Biogen is known for its pioneering work in the neuroscience field. It has been discovering and…

October 24, 2024 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 27 May 2025

Interleukin therapeutics: 9 companies to follow in 2025

…for ANK-101 at the AACR Annual Meeting Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of cytokine-based treatments. The company’s lead candidate, ANK-101 (tolododekin…

May 27, 2025 - 12 minutesmins - By Jules Adam

In Depth 22 Dec 2022

10 biotech companies to watch in 2023

…candidates — called TCR-T cell therapies — are designed to tackle solid cancers. This is because they are genetically modified to express a custom version of a T-cell protein called…

December 22, 2022 - 9 minutesmins - By Jonathan Smith

Best in Biotech 24 Jul 2025

Which biotech companies are gaining traction in genetic diseases?

…to advance treatments for genetic diseases. Table of contents Actio Biosciences Headquarters: San Diego, U.S.A. Latest funding round: $66 million series B (June 2025) Lead candidates: ABS‑1230 for KCNT1-related epilepsy;…

July 24, 2025 - 12 minutesmins - By Jules Adam

News and Trends 30 Apr 2018

Record Series B Financing Supports Antibody Cancer Therapy

…of antibody-based therapies for cancer has recently been on the rise in European biotech. For example, late last year Argenx raised €195M to support the clinical development of its antibody…

April 30, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 4 Jun 2020

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate…

June 4, 2020 - 4 minutesmins - By Anita Chakraverty

News and Trends 31 May 2017

German Biotech Enters the Clinic with Next-Generation Antibody for AML

…immunotherapy candidate, TacSyn, to treat patients at a stage of existing disease of AML as well as acute lymphoblastic leukemia (ALL). This bispecific antibody contains an anti-CD3 domain, which is…

May 31, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

The EU Approves New Treatment for a Rare Pediatric Cancer

…Human Use (CHMP) has now given a positive opinion on APN311, recommending the approval of the new drug. APN311 is a monoclonal antibody targeting the neuroblastoma-specific antigen GD2. The antibody…

May 8, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

The future of NSCLC treatment: what’s in store for the therapeutic space?

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

Six biotech companies advancing multiple sclerosis therapies

Interleukin therapeutics: 9 companies to follow in 2025

10 biotech companies to watch in 2023

Which biotech companies are gaining traction in genetic diseases?

Record Series B Financing Supports Antibody Cancer Therapy

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

German Biotech Enters the Clinic with Next-Generation Antibody for AML

The EU Approves New Treatment for a Rare Pediatric Cancer

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!